Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.31 |
| ▸ | RELA | Q04206 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16197721 | 0.86 | CTSK (0.39) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL14023369 | 0.83 | CPB2 (0.35) | HDAC6HDAC1HDAC2CPB2CA14 | |
| SCHEMBL6620920 | 0.83 | L3MBTL1 (0.43) | — | |
| SCHEMBL6517339 | 0.80 | HDAC6 (0.41) | HDAC6HDAC1HDAC2CPB2CA14 | |
| SCHEMBL3747931 | 0.80 | CA14 (0.40) | HDAC6HDAC1HDAC2CPB2CA14 | |
| SCHEMBL16205771 | 0.79 | CTSK (0.36) | HDAC6HDAC1HDAC2CA14CTSK | |
| SCHEMBL21651913 | 0.77 | CA12 (0.40) | HDAC6HDAC1HDAC2CPB2CA14 | |
| SCHEMBL137000 | 0.77 | HDAC6 (0.46) | HDAC6HDAC1HDAC2CPB2CA14 | |
| SCHEMBL14396847 | 0.75 | CA14 (0.41) | HDAC6HDAC1HDAC2CPB2CA14 | |
| SCHEMBL13109069 | 0.75 | CA14 (0.39) | HDAC6HDAC1HDAC2CPB2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024216075-A1 | SYNTHESIS OF MAVORIXAFOR AND INTERMEDIATES THEREOF | X4 PHARMACEUTICALS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| US-11672793-B2 | Compositions of CXCR4 inhibitors and methods of preparation and use | X4 PHARMACEUTICALS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| WO-2020047410-A1 | COMPOSITIONS OF CXCR4 INHIBITORS AND METHODS OF PREPARATION AND USE | X4 PHARMACEUTICALS, INC. (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11672793-B2 | Compositions of CXCR4 inhibitors and methods of preparation and use | CXCR4, CXCL12, CXCR1 | HDAC6 388/4885HDAC1 743/4885HDAC2 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.